



# PERSISTENCE ANALYSIS WITH ANTI CALCITONIN GENE-RELATED PEPTIDE PROPHYLACTIC TREATMENTS IN PATIENTS WITH MIGRAINE

Maraver-Villar V, Gómez-Bermejo M, Sánchez-Rubio Ferrández J, Onteniente-González A, Molina-García T

## Background and Importance

### MONOCLONAL ANTIBODIES and CGRP RECEPTOR ANTAGONISTS in MIGRAINE PROPHYLAXIS

These treatments have proven effective in reducing both the frequency and severity of migraine episodes



## Aim and Objectives

To compare the **persistence** of different anti-CGRP treatments in patients with migraine

## Materials and Methods

A retrospective, non-interventional, longitudinal study  
Patients with chronic or episodic migraine treated with an **anti-CGRP drug** at our centre

**PERSISTENCE**  
Duration of time from treatment initiation to discontinuation



## Results

### PATIENT CHARACTERISTICS

285 patients were included (84.9% female, 15.1% male)  
Age (mean±SD) 49.8 ± 11.9 years

**Median persistence duration**  
451 days (CI95%: 311-590)  
Females: 490 days (CI95%: 345-635)  
Males: 260 days (CI95%: 159-360)

### TREATMENT LINE

First: 464 days (CI95%: 283-645)  
Second: 356 days (CI95% 0-716)  
Third: 490 days (CI95% 356-624)  
Fourth: 221 days (CI95% 94-348)

### TREATMENT DISTRIBUTION & PERSISTENCE:

Fremanezumab	51.2%	464 days (CI95% 258-669)
Erenumab	19.6%	246 days (CI95% 75-417)
Galcanezumab	8.4%	172 days (CI95% 0-609)
Eptinezumab	14.4%	581 days (CI95% 458-703)
Atogepant	6.0%	311 days (CI95% 147-475)
Rimegepant	0.45%	326 days (not reached)

There were no statistically significant differences between the groups

There were no statistically significant differences between the groups

**Subcutaneous group (fremanezumab, erenumab, galcanezumab; n=226)**

- 84.1% were female and 15.9% male
- 64.6% fremanezumab
- 24.8% erenumab
- 10.6% galcanezumab
- 75.7% first-line therapy, 21.7% second, 2.7% third

Significant differences were found between erenumab and fremanezumab (HR = 0.53; 95% CI 0.32-0.89; p=0.015)

## Conclusion and Relevance

- ✓ There were **no statistically significant differences** in persistence between anti-CGRP therapies in our study.
- ✓ Higher persistence rates were observed for eptinezumab and fremanezumab.
- ✓ Among subcutaneous agents, **fremanezumab demonstrated significantly greater persistence compared with erenumab.**

